Patent Grant
9005277
The present invention generally relates to prosthetic valves for implantation in body channels. More particularly, the present invention relates to systems for deploying unitary prosthetic heart valves configured to be surgically implanted in less time than current valves.
In vertebrate animals, the heart is a hollow muscular organ having four pumping chambers as seen in FIG. 1—the left and right atria and the left and right ventricles, each provided with its own one-way valve. The natural heart valves are identified as the aortic, mitral (or bicuspid), tricuspid and pulmonary, and are each mounted in an annulus comprising dense fibrous rings attached either directly or indirectly to the atrial and ventricular muscle fibers. Each annulus defines a flow orifice.
The atria are the blood-receiving chambers, which pump blood into the ventricles. The ventricles are the blood-discharging chambers. A wall composed of fibrous and muscular parts, called the interatrial septum separates the right and left atria (see
The synchronous pumping actions of the left and right sides of the heart constitute the cardiac cycle. The cycle begins with a period of ventricular relaxation, called ventricular diastole. The cycle ends with a period of ventricular contraction, called ventricular systole. The four valves (see
The mitral and tricuspid valves are defined by fibrous rings of collagen, each called an annulus, which forms a part of the fibrous skeleton of the heart. The annulus provides peripheral attachments for the two cusps or leaflets of the mitral valve (called the anterior and posterior cusps) and the three cusps or leaflets of the tricuspid valve. The free edges of the leaflets connect to chordae tendineae from more than one papillary muscle, as seen in
When the left ventricle contracts after filling with blood from the left atrium, the walls of the ventricle move inward and release some of the tension from the papillary muscle and chords. The blood pushed up against the under-surface of the mitral leaflets causes them to rise toward the annulus plane of the mitral valve. As they progress toward the annulus, the leading edges of the anterior and posterior leaflet come together forming a seal and closing the valve. In the healthy heart, leaflet coaptation occurs near the plane of the mitral annulus. The blood continues to be pressurized in the left ventricle until it is ejected into the aorta. Contraction of the papillary muscles is simultaneous with the contraction of the ventricle and serves to keep healthy valve leaflets tightly shut at peak contraction pressures exerted by the ventricle.
Various surgical techniques may be used to repair a diseased or damaged valve. In a valve replacement operation, the damaged leaflets are excised and the annulus sculpted to receive a replacement valve. Due to aortic stenosis and other heart valve diseases, thousands of patients undergo surgery each year wherein the defective native heart valve is replaced by a prosthetic valve, either bioprosthetic or mechanical. Another less drastic method for treating defective valves is through repair or reconstruction, which is typically used on minimally calcified valves. The problem with surgical therapy is the significant insult it imposes on these chronically ill patients with high morbidity and mortality rates associated with surgical repair.
When the valve is replaced, surgical implantation of the prosthetic valve typically requires an open-chest surgery during which the heart is stopped and patient placed on cardiopulmonary bypass (a so-called “heart-lung machine”). In one common surgical procedure, the diseased native valve leaflets are excised and a prosthetic valve is sutured to the surrounding tissue at the valve annulus. Because of the trauma associated with the procedure and the attendant duration of extracorporeal blood circulation, some patients do not survive the surgical procedure or die shortly thereafter. It is well known that the risk to the patient increases with the amount of time required on extracorporeal circulation. Due to these risks, a substantial number of patients with defective valves are deemed inoperable because their condition is too frail to withstand the procedure. By some estimates, about 30 to 50% of the subjects suffering from aortic stenosis who are older than 80 years cannot be operated on for aortic valve replacement.
Because of the drawbacks associated with conventional open-heart surgery, percutaneous and minimally-invasive surgical approaches are garnering intense attention. In one technique, a prosthetic valve is configured to be implanted in a much less invasive procedure by way of catheterization. For instance, U.S. Pat. No. 5,411,552 to Andersen et al. describes a collapsible valve percutaneously introduced in a compressed state through a catheter and expanded in the desired position by balloon inflation. Although these remote implantation techniques have shown great promise for treating certain patients, replacing a valve via surgical intervention is still the preferred treatment procedure. One hurdle to the acceptance of remote implantation is resistance from doctors who are understandably anxious about converting from an effective, if imperfect, regimen to a novel approach that promises great outcomes but is relatively foreign. In conjunction with the understandable caution exercised by surgeons in switching to new techniques of heart valve replacement, regulatory bodies around the world are moving slowly as well. Numerous successful clinical trials and follow-up studies are in process, but much more experience with these new technologies will be required before they are completely accepted.
Accordingly, there is a need for an improved device and associated method of use wherein a prosthetic valve can be surgically implanted in a body channel in a more efficient procedure that reduces the time required on extracorporeal circulation. It is desirable that such a device and method be capable of helping patients with defective valves that are deemed inoperable because their condition is too frail to withstand a lengthy conventional surgical procedure.
Furthermore, surgeons relate that one of the most difficult tasks when attempting minimally invasive heart valve implantation or implantation through a small incision is tying the suture knots that hold the valve in position. A typical aortic valve implant utilizes 12-24 sutures (commonly 15) distributed evenly around and manually tied on one side of the sewing ring. The knots directly behind the commissure posts are particularly challenging because of space constraints. Eliminating the need to tie suture knots or even reducing the number of knots to those that are more accessible would greatly facilitate the use of smaller incisions that reduces infection risk, reduces the need for blood transfusions and allows more rapid recovery compared to patients whose valves are implanted through the full sternotomy commonly used for heart valve implantation.
The present invention addresses these needs and others.
Various embodiments of the present application provide prosthetic valves and methods of use for replacing a defective native valve in a human heart. Certain embodiments are particularly well adapted for use in a surgical procedure for quickly and easily replacing a heart valve while minimizing time using extracorporeal circulation (i.e., bypass pump).
In one embodiment, a method for treating a native aortic valve in a human heart to replaces the function of the aortic valve, comprises: 1) accessing a native valve through an opening in a chest; 2) placing guiding sutures in the annulus 3) advancing a heart valve within a lumen of the annulus; and 4) plastically expanding a metallic coupling stent on the heart valve to mechanically couple to the annulus in a quick and efficient manner.
The native valve leaflets may be removed before delivering the prosthetic valve. Alternatively, the native leaflets may be left in place to reduce surgery time and to provide a stable base for fixing the coupling stent within the native valve. In one advantage of this method, the native leaflets recoil inward to enhance the fixation of the metallic coupling stent in the body channel. When the native leaflets are left in place, a balloon or other expansion member may be used to push the valve leaflets out of the way and thereby dilate the native valve before implantation of the coupling stent. The native annulus may be dilated between 1.0-5 mm from their initial orifice size to accommodate a larger sized prosthetic valve.
In accordance with a preferred aspect, a heart valve includes a prosthetic valve defining therein a non-expandable, non-collapsible orifice, and an expandable coupling stent extending from an inflow end thereof. The coupling stent has a contracted state for delivery to an implant position and an expanded state configured for outward connection to the base stent. Desirably, the coupling stent is plastically expandable.
In another aspect, a prosthetic heart valve for implant at a heart valve annulus, comprises:
a. a non-expandable, non-collapsible annular support structure defining a flow orifice, the support structure including a plurality of commissure posts projecting in an outflow direction;
b. flexible leaflets attached to the support structure and commis sure posts and mounted to alternately open and close across the flow orifice;
c. a suture-permeable ring circumscribing an inflow end of the support structure; and
d. a plastically-expandable coupling stent having a first end extending around and connected at the inflow end of the support structure, the coupling stent having a second end projecting in the inflow direction away from the valve support structure and being capable of assuming a contracted state for delivery to an implant position and an expanded state wider than the first end for outward contact with an annulus.
In one embodiment, the heart valve comprises a commercially available prosthetic valve having a sewing ring, and the coupling stent attaches to the sewing ring. The contracted state of the coupling stent may be conical, tapering down in a distal direction. The coupling stent preferably comprises a plurality of radially expandable struts at least some of which are arranged in rows, wherein the distalmost row has the greatest capacity for expansion from the contracted state to the expanded state.
A method of delivery and implant of a prosthetic heart valve system is also disclosed herein, comprising the steps of:
providing a heart valve including a prosthetic valve having a non-expandable, non-collapsible orifice, the heart valve further including an expandable coupling stent extending from an inflow end thereof, the coupling stent having a contracted state for delivery to an implant position and an expanded state configured for outward connection to the annulus;
advancing the heart valve with the coupling stent in its contracted state to an implant position adjacent the annulus; and
plastically expanding the coupling stent to the expanded state in contact with and connected to the annulus.
One embodiment of the method further includes mounting the heart valve on a holder having a proximal hub and lumen therethrough. The holder mounts on the distal end of a handle having a lumen therethrough, and the method including passing a balloon catheter through the lumen of the handle and the holder and within the heart valve, and inflating a balloon on the balloon catheter to expand the coupling stent. The heart valve mounted on the holder may be packaged separately from the handle and the balloon catheter. Desirably, the contracted state of the coupling stent is conical, and the balloon on the balloon catheter has a larger distal expanded end than its proximal expanded end so as to apply greater expansion deflection to the coupling stent than to the prosthetic valve.
In the method where the coupling stent is conical, the coupling stent may comprise a plurality of radially expandable struts at least some of which are arranged in rows, wherein the row farthest from the prosthetic valve has the greatest capacity for expansion from the contracted state to the expanded state.
The method may employ a coupling stent with a plurality of radially expandable struts, wherein a row farthest from the prosthetic valve has alternating peaks and valleys. The distal end of the coupling stent thus expands more than the rest of the coupling stent so that the peaks in the row farthest from the prosthetic valve project outward into apertures in the base stent.
Another aspect described herein is a system for delivering a heart valve including a prosthetic valve having a non-expandable, non-collapsible orifice, and an expandable coupling stent extending from an inflow end thereof, the coupling stent having a contracted state for delivery to an implant position and an expanded state. The delivery system includes a valve holder connected to a proximal end of the heart valve, a balloon catheter having a balloon, and a handle configured to attach to a proximal end of the valve holder and having a lumen for passage of the catheter, wherein the balloon extends distally through the handle, past the holder and through the heart valve. In the system, the prosthetic valve is preferably a commercially available valve having a sewing ring to which the coupling stent attaches.
The contracted state of the coupling stent in the delivery system may be conical, tapering down in a distal direction. Furthermore, the balloon catheter further may include a generally conical nose cone on a distal end thereof that extends through the heart valve and engages a distal end of the coupling stent in its contracted state. Desirably, the handle comprises a proximal section and a distal section that may be coupled together in series to form a continuous lumen, wherein the distal section is adapted to couple to the hub of the holder to enable manual manipulation of the heart valve using the distal section prior to connection with the proximal handle section. In one embodiment, the balloon catheter and proximal handle section are packaged together with the balloon within the proximal section lumen. Alternatively, the heart valve mounted on the holder is packaged separately from the handle and the balloon catheter.
A further understanding of the nature and advantages of the present invention are set forth in the following description and claims, particularly when considered in conjunction with the accompanying drawings in which like parts bear like reference numerals.
The invention will now be explained and other advantages and features will appear with reference to the accompanying schematic drawings wherein:
The present invention attempts to overcome drawbacks associated with conventional, open-heart surgery, while also adopting some of the techniques of newer technologies which decrease the duration of the treatment procedure. The prosthetic heart valves of the present invention are primarily intended to be delivered and implanted using conventional surgical techniques, including the aforementioned open-heart surgery. There are a number of approaches in such surgeries, all of which result in the formation of a direct access pathway to the particular heart valve annulus. For clarification, a direct access pathway is one that permits direct (i.e., naked eye) visualization of the heart valve annulus. In addition, it will be recognized that embodiments of the unitary prosthetic heart valves described herein may also be configured for delivery using percutaneous approaches, and those minimally-invasive surgical approaches that require remote implantation of the valve using indirect visualization.
One primary aspect of the present invention is a unitary prosthetic heart valve including implanting a tissue anchor at the same time as a valve member resulting in certain advantages. The exemplary unitary prosthetic heart valve of the present invention has a hybrid valve member with non-expandable and expandable portions. By utilizing an expandable stent coupled to a non-expandable valve member, the duration of the anchoring operation is greatly reduced as compared with a conventional sewing procedure utilizing an array of sutures. The expandable stent may simply be radially expanded outward into contact with the implantation site, or may be provided with additional anchoring means, such as barbs. The operation may be carried out using a conventional open-heart approach and cardiopulmonary bypass. In one advantageous feature, the time on bypass is greatly reduced due to the relative speed of implanting the expandable stent.
For definitional purposes, the terms “stent” or “coupling stent” refer to a structural component of a heart valve that is capable of attaching to tissue of a heart valve annulus. The coupling stents described herein are most typically tubular stents, or stents having varying shapes or diameters. A stent is normally formed of a biocompatible metal frame, such as stainless steel or Nitinol. More preferably, in the context of the present invention the stents are made from laser-cut tubing of a plastically-expandable metal. Other coupling stents that could be used with valves of the present invention include rigid rings, spirally-wound tubes, and other such tubes that fit tightly within a valve annulus and define an orifice therethrough for the passage of blood. It is entirely conceivable, however, that the coupling stent could be separate clamps or hooks that do not define a continuous periphery. Although such devices sacrifice some contact uniformity, and speed and ease of deployment, these devices could be configured to work in conjunction with a particular valve member.
A distinction between self-expanding and balloon-expanding stents exists in the field. A self-expanding stent may be crimped or otherwise compressed into a small tube and possesses sufficient elasticity to spring outward by itself when a restraint such as an outer sheath is removed. In contrast, a balloon-expanding stent is made of a material that is substantially less elastic, and indeed must be plastically expanded from the inside out when converting from a contracted to an expanded diameter. It should be understood that the term balloon-expanding stents encompasses plastically-expandable stents, whether or not a balloon is used to actually expand it (e.g., a device with mechanical fingers could expand the stent). The material of the stent plastically deforms after application of a deformation force such as an inflating balloon or expanding mechanical fingers. Consequently, the term “balloon-expandable stent” should be considered to refer to the material or type of the stent as opposed to the specific expansion means.
The term “valve member” refers to that component of a heart valve that possesses the fluid occluding surfaces to prevent blood flow in one direction while permitting it in another. As mentioned above, various constructions of valve members are available, including those with flexible leaflets and those with rigid leaflets, or even a ball and cage arrangement. The leaflets may be bioprosthetic, synthetic, metallic, or other suitable expedients.
A primary focus of the present invention is a unitary prosthetic heart valve having a single stage implantation in which a surgeon secures a hybrid coupling stent and valve member to a valve annulus as one unit or part. Certain features of the hybrid coupling stent and valve member are described in co-pending U.S. Provisional Application No. 61/139,398, filed Dec. 19, 2008, the contents of which are expressly incorporated herein. It should be noted that “two-stage” prosthetic valve delivery disclosed in the aforementioned application refers to the two primary steps of a) anchoring structure to the annulus, and then b) connecting a valve member, which does not necessarily limit the valve to just two parts. Likewise, the unitary valve described herein is especially beneficial in a single stage implant procedure, but that does not necessarily limit the overall system to just one part. For instance, the heart valve 30 disclosed herein could also use an expanding base stent which is then reinforced by the subsequently implanted heart valve. Because the heart valve 30 has a non-expandable and non-collapsible annular support structure, and a plastically-expandable coupling stent 36, it effectively resists recoil of a self-expanded base stent. That said, various claims appended hereto may exclude more than one part.
As a point of further definition, the term “expandable” is used herein to refer to a component of the heart valve capable of expanding from a first, delivery diameter to a second, implantation diameter. An expandable structure, therefore, does not mean one that might undergo slight expansion from a rise in temperature, or other such incidental cause such as fluid dynamics acting on leaflets or commissures. Conversely, “non-expandable” should not be interpreted to mean completely rigid or a dimensionally stable, as some slight expansion of conventional “non-expandable” heart valves, for example, may be observed.
In the description that follows, the term “body channel” is used to define a blood conduit or vessel within the body. Of course, the particular application of the prosthetic heart valve determines the body channel at issue. An aortic valve replacement, for example, would be implanted in, or adjacent to, the aortic annulus. Likewise, a mitral valve replacement will be implanted at the mitral annulus. Certain features of the present invention are particularly advantageous for one implantation site or the other, in particular the aortic annulus. However, unless the combination is structurally impossible, or excluded by claim language, any of the heart valve embodiments described herein could be implanted in any body channel.
A “quick-connect” aortic valve bio-prosthesis described herein is a surgically-implanted medical device for the treatment of aortic valve stenosis. The exemplary quick-connect device comprises an implantable bio-prosthesis and a delivery system for its deployment. The device, delivery system and method of use take advantage of the proven hemodynamic performance and durability of existing commercially available, non-expandable prosthetic heart valves, such as the Carpentier-Edwards PERIMOUNT Magna® Aortic Heart Valve available from Edwards Lifesciences of Irvine, Calif., while improving its ease of use and reducing total procedure time. This is mainly accomplished by eliminating the need to suture the bio-prosthesis onto the native annulus as is currently done per standard surgical practice, and typically requires 12-24 manually tied sutures around the valve perimeter. Also, the technique may obviate the need to excise the leaflets of the calcified valve and debride or smooth the valve annulus.
When used for aortic valve replacement, the prosthetic valve 34 preferably has three flexible leaflets which provide the fluid occluding surfaces to replace the function of the native valve leaflets. In various preferred embodiments, the valve leaflets may be taken from another human heart (cadaver), a cow (bovine), a pig (porcine valve) or a horse (equine). In other preferred variations, the valve member may comprise mechanical components rather than biological tissue. The three leaflets are supported by a non-expandable, non-collapsible annular support structure and a plurality of commissure posts projecting in an outflow direction. Typical prosthetic heart valves with flexible leaflets include a synthetic (metallic and/or polymeric) support structure of one or more components covered with cloth for ease of attachment of the leaflets.
For instance, in a preferred embodiment, the prosthetic valve 34 comprises a commercially available, non-expandable prosthetic heart valve, such as the Carpentier-Edwards PERIMOUNT Magna® Aortic Heart Valve available from Edwards Lifesciences. In this sense, a “commercially available” prosthetic heart valve is an off-the-shelf (i.e., suitable for stand-alone sale and use) prosthetic heart valve defining therein a non-expandable, non-collapsible support structure and having a sewing ring capable of being implanted using sutures through the sewing ring in an open-heart, surgical procedure. The particular approach into the heart used may differ, but in surgical procedures the heart is stopped and opened, in contrast to beating heart procedures where the heart remains functional. To reiterate, the terms “non-expandable” and “non-collapsible” should not be interpreted to mean completely rigid and dimensionally stable, merely that the valve is not expandable/collapsible like some proposed minimally-invasively or percutaneously-delivered valves.
The prosthetic valve 34 is provided with an expandable coupling mechanism in the form of the coupling stent 36 for securing the valve to the annulus. Although the coupling stent 36 is shown, the coupling mechanism may take a variety of different forms, but eliminates the need for connecting sutures and provides a rapid connection means as it does not require the time-consuming process of suturing it to the annulus.
An implant procedure involves delivering the heart valve 30 and expanding the coupling stent 36 at the aortic annulus. Because the valve 34 is non-expandable, the entire procedure is typically done using the conventional open-heart technique. However, because the coupling stent 36 is implanted by simple expansion, with reduced suturing, the entire operation takes less time. This hybrid approach will also be much more comfortable to surgeons familiar with the open-heart procedures and commercially available heart valves.
Moreover, the relatively small change in procedure coupled with the use of proven heart valves should create a much easier regulatory path than strictly expandable, remote procedures. Even if the system must be validated through clinical testing to satisfy the Pre-Market Approval (PMA) process with the FDA (as opposed to a 510 k submission), at least the surgeon acceptance of the quick-connect heart valve 30 will be greatly streamlined with a commercial heart valve that is already proven, such as the Magna® Aortic Heart Valve.
In
In a preferred embodiment, the coupling stent 36 comprises a plastically-expandable cloth-covered stainless-steel tubular stent. One advantage of using a plastically-expandable stent is the ability to expand the native annulus to receive a larger valve size than would otherwise be possible with conventional surgery. Desirably, the left ventricular outflow tract (LVOT) is significantly expanded by at least 10%, or for example by 1.0-5 mm, and the surgeon can select a heart valve 30 with a larger orifice diameter relative to an unexpanded annulus. Even a 1 mm increase in annulus size is significant since the gradient is considered to be proportional to the radius raised to the 4th power.
The stent body is preferably configured with sufficient radial strength for pushing aside the native leaflets and holding the native leaflets open in a dilated condition. The native leaflets provide a stable base for holding the stent, thereby helping to securely anchor the stent in the body. To further secure the stent to the surrounding tissue, the lower portion may be configured with anchoring members, such as, for example, hooks or barbs (not shown). It should be understood that the coupling stent 36 is desirably robust enough to anchor the heart valve 30 directly against the native annulus (with or without leaflet excision) in the absence of a pre-deployed base stent.
Also, the balloon 40 may have a larger distal expanded end than its proximal expanded end so as to apply more force to the free end of the coupling stent 36 than to the prosthetic valve 34. In this way, the prosthetic valve 34 and flexible leaflets therein are not subject to high expansion forces from the balloon 40. Indeed, although balloon deployment is shown, the coupling stent 36 may also be a self-expanding type of stent. In the latter configuration, the nose cone 38 is adapted to retain the coupling stent 36 in its constricted state prior to position in the heart valve 30 within the aortic annulus.
As noted above, the coupling stent 36 described herein can be a variety of designs, including having the diamond/chevron-shaped openings shown or other configurations. Further, the coupling stent 36 may include barbs or other tissue anchors to further secure the stent to the tissue. The barbs could be deployable (e.g., configured to extend or be pushed radially outward) by the expansion of a balloon. Alternatively, shape memory material may be utilized such that the barbs bend or curl upon implant. The material of the coupling stent 36 depends on the mode of delivery (i.e., balloon- or self-expanding), and the stent can be bare strut material or covered to promote ingrowth and/or to reduce paravalvular leakage. Preferably, the coupling stent 36 is covered to promote in-growth and/or to reduce paravalvular leakage, such as with a Dacron tube or the like.
The aforementioned nose cone 38 may attach to the distalmost end of the catheter 52, but more preferably attaches to a wire (not shown) inserted through the center lumen of the balloon catheter 52. The nose cone 38 preferably secures to the end of a 0.035″ guide wire and has a tapered geometry that fits onto the tapered geometry of the tapered coupling stent 36 to protect it and prevent accidental calcium dislodgement caused by the stent catching as it advances into the native calcified aortic valve. The nose cone 38 assembles onto the distal end of the heart valve 30 prior to positioning the device into the aortic root for deployment. The nose cone 38 is assembled by distally loading the guide wire into the through lumen of the balloon catheter 52 and advancing distally until it sits and conforms to the tapered coupling stent 36. Once the prosthesis is in the desired location and prior to balloon expansion, the surgeon advances the nose cone 38 in the ventricular direction to allow balloon expansion. As it advances in the ventricular direction and disengages the stent frame, the nose cone 38 collapses to a size that allows retrieval through the deployed aortic valve.
The catheter 52 and the nose cone 38 pass through a hollow handle 60 having a proximal section 62 and a distal section 64. A distal end of the distal handle section 64 firmly attaches to a hub 66 of a valve holder 68, which in turn attaches to the prosthetic heart valve 30. Details of the valve holder 68 will be given below with reference to
The two sections 62, 64 of the handle 60 are desirably formed of a rigid material, such as a molded plastic, and coupled to one another to form a relatively rigid and elongated tube for manipulating the prosthetic heart valve 30 attached to its distal end. In particular, the distal section 64 may be easily coupled to the holder hub 66 and therefore provide a convenient tool for managing the heart valve 30 during pre-surgical rinsing steps. For this purpose, the distal section 64 features a distal tubular segment 70 that couples to the holder hub 66, and an enlarged proximal segment 72 having an opening on its proximal end that receives a tubular extension 74 of the proximal handle section 62.
In a preferred embodiment, the prosthetic heart valve 30 incorporates bioprosthetic tissue leaflets and is packaged and stored attached to the holder 68 but separate from the other introduction system 50 components. Typically, bioprosthetic tissue is packaged and stored in a jar with preservative solution for long shelf life, while the other components are packaged and stored dry.
When assembled as seen in
As explained above with respect to
Prior to a further description of operation of the delivery system 50, a more detailed explanation of the heart valve 30 and valve holder 68 is necessary.
The coupling stent 36 preferably attaches to the ventricular (or inflow) aspect of the valve's sewing ring 42 during the manufacturing process in a way that preserves the integrity of the sewing ring and prevents reduction of the valve's effective orifice area (EOA). Desirably, the coupling stent 36 will be continuously sutured to the sewing ring 42 in a manner that maintains the outer contours of the sewing ring. Sutures may be passed through apertures or eyelets in the stent skeleton, or through a cloth covering that in turn is sewn to the skeleton. Other connection solutions include prongs or hooks extending inward from the stent, ties, Velcro, snaps, adhesives, etc. Alternatively, the coupling stent 36 may be more rigidly connected to rigid components within the prosthetic valve 34. During implant, therefore, the surgeon can seat the sewing ring 42 against the annulus in accordance with a conventional surgery. This gives the surgeon familiar tactile feedback to ensure that the proper patient-prosthesis match has been achieved. Moreover, placement of the sewing ring 42 against the outflow side of the annulus helps reduce the probability of migration of the heart valve 30 toward the ventricle.
The coupling stent 36 may be a pre-crimped, tapered, 316L stainless steel balloon-expandable stent, desirably covered by a polyester skirt 88 to help seal against paravalvular leakage and promote tissue ingrowth once implanted within the annulus (see
The coupling stent 36 desirably comprises a plurality of sawtooth-shaped or otherwise angled, serpentine or web-like struts 90 connected to three generally axially-extending posts 92. As will be seen below, the posts 92 desirably feature a series of evenly spaced apertures to which sutures holding the polyester skirt 88 in place may be anchored. As seen best in
It should be understood that the particular configuration of the coupling stent, whether possessing straight or curvilinear struts 90, may be modified as needed. There are numerous stent designs, as described below with reference to
Still with reference to
In one embodiment, the holder 68 is formed of a rigid polymer such as Delrin or polypropylene that is transparent to increase visibility of an implant procedure. As best seen in
The gaps between the lengths making up the reinforcing ring 126 permit the stent 120 to be matched with a number of different sized prosthetic valves 34. That is, the majority of the stent 120 is expandable having a variable diameter, and providing gaps in the reinforcing ring 126 allows the upper end to also have a variable diameter so that it can be shaped to match the size of the corresponding sewing ring. This reduces manufacturing costs as correspondingly sized stents need not be used for each different sized valve.
In
As an alternative to a balloon, a mechanical expander (not shown) may be used to expand the coupling stent 36 shown above. For instance, a mechanical expander may include a plurality of spreadable fingers actuated by a syringe-like apparatus, as seen in U.S. Provisional Application No. 61/139,398, incorporated above. The fingers are axially fixed but capable of pivoting or flexing with respect to a barrel. The distal end of a plunger has an outer diameter that is greater than the diameter circumscribed by the inner surfaces of the spreadable fingers, such that distal movement of the plunger with respect to the barrel gradually cams the fingers outward within the coupling stent. Therefore, the term “plastically-expandable” encompasses materials that can be substantially deformed by an applied force to assume a different shape. Some self-expanding stents may be deformed to a degree by an applied force beyond their maximum expanded dimension, but the primary cause of the shape change is elastic rebound as opposed to a plastic deformation.
The unitary heart valve 30 described above may be mounted on a balloon catheter advanced into implant position thereon, or the balloon catheter may be introduced after the valve has been delivered to the annulus.
In
The leaflet parting sleeve 204 mounts to one end of an assembly tube 220. Although not shown, the sleeve 204 preferably fits snugly over the end of the tube 220 with a slight interference, so that it may be decoupled therefrom with ease. Some form of minimal latch may also be provided. The coupling stent 202 has a first end (not shown) connected to the inflow end of the prosthetic valve 208 and a lower second end 222 that is shown in a contracted state for delivery to an implant position. In the contracted state, the coupling stent 202 assumes a frusto-conical shape wherein the lower second end 222 defines an opening large enough to receive the leaflet parting sleeve 204 with clearance therebetween. The sleeve 204 includes internal threading 224 that matches external threading on a downwardly-directed boss 226 of the valve holder 206. A technician passes the sleeve 204 on the end of the tube 220 through the stent second end 222, parts the flexible leaflets 210 from the inflow side, and screws the sleeve to the boss 226. Once the technician firmly attaches the sleeve 204, the assembly tube 220 may be easily pulled from and removed from within the valve 200. The resulting subassembly is seen in
Attachment of the leaflet parting sleeve 204 in this manner provides several benefits. First and foremost, the sleeve 204 defines a throughbore at the level of the valve leaflets 210 for passage of a balloon catheter from the outflow side. Typically three valve leaflets 210 span the orifice defined by the support structure 212 and have free edges that come together or “coapt” generally along three line segments oriented 120° apart that intersect at the centerline. This configuration mimics a native valve and performs well in permitting blood flow in one direction but not the other. Though extremely durable in use, the valve leaflets 210 are relatively fragile and susceptible to damage from contact with solid objects during the implant procedure, especially if they are made from bioprosthetic tissue such as bovine pericardium or a porcine xenograft. Consequently, the parting sleeve 204 opens the leaflets 210 and provides a protective barrier between them and a balloon catheter that passes through the valve, as will be seen below. Without the sleeve 204 a balloon catheter would have to force its way backward past the coapted leaflet free edges. A further benefit of the parting sleeve 204 is the ease with which it is assembled to the holder 206. Attachment through the valve 200 to the holder 206 is intuitive, and removal of the assembly sleeve 220 simple. The valve 220 and holder 206 assembly are stored together prior to use, often in a storage solution of glutaraldehyde or other preservative. The parting sleeve 204 is preferably not pre-attached to the holder 206 to avoid causing any indentations in the leaflets 210 from long-term contact therewith. That is, the leaflets 210 are stored in their relaxed or coapted state.
The surgeon attaches the guide sutures 230 at three evenly spaced locations around the aortic annulus AA. In the illustrated embodiment, the guide sutures 230 attach to locations below or corresponding to the coronary ostia CO (that is, two guide sutures are aligned with the ostia, and the third centered below the non-coronary sinus). The guide sutures 230 are shown looped twice through the annulus AA from the outflow or ascending aorta side to the inflow or ventricular side. Of course, other suturing methods or pledgets may be used depending on surgeon preference.
Now with reference to
The surgeon delivers a plurality of suture snares 250 down each free length of the guide sutures 230 into contact with the upper or outflow side of the suture-permeable ring 216. The snares 250 enable downward pressure to be applied to the ring 216 and thus the valve 200 during the implant procedure, which helps insure good seating of the ring 216 on the annulus AA. The snares 250 also provide rigid enclosures around each of the flexible guide sutures 230 which helps avoid entanglement with the descending balloon catheter, as will be appreciated. As there are three guide sutures 230 and six free lengths, six snares 250 are utilized, though more or less is possible. The snares 250 are typically tubular straw-like members of medical grade plastic.
In
Now with reference to
Subsequently, the surgeon delivers three fastener clips 270 down the guide sutures 230 after removal of the snares 250, as seen in
The illustrated configuration with fastener clips 270 eliminates the need to tie suture knots, and the placement of the guide sutures 230 at the cusps of the native valve and prosthesis separates the clips from the commissures, thus increasing accessibility. Even if knots are used instead of the clips 270, the number of knots are reduced to three between the commissure posts, rather than multiple knots (12-24) as before, some of which were behind the commissure posts. The use of three sutures correctly positions the valve 200 and centering the sutures between the commissure posts is the most accessible for tying knots because the cusps are the lowest points in the annulus. Placement of knots (or clips) at the lowest point in the annulus also helps minimize the risk of coronary occlusion.
A more detailed understanding of the unitary heart valve 200 and holder 206 follows with reference to
As explained above, the prosthetic valve 208 has three flexible leaflets 210 supported by a non-expandable, non-collapsible annular support structure 212 and a plurality of commissure posts 214 projecting in an outflow direction, with a suture-permeable ring 216 circumscribing an inflow end thereof. In one embodiment, the heart valve 200 is a commercially available, non-expandable prosthetic heart valve 208 having a sewing ring 216, such as a Carpentier-Edwards PERIMOUNT Magna Aortic Bioprosthesis valve, attached to a pre-crimped tapered Stainless Steel coupling stent 202 lined and/or covered by a fabric (e.g., Dacron) skirt 218, as seen in
As seen in
Each anchoring finger 229 includes a generally flat lower face 233 bordered on an outer edge by a downwardly-extending U-shaped rail 234. A plurality of through holes 235 extend axially through each finger 229 to an upper surface, as seen in
The coupling stent 202 (shown separated in
The plastically-expandable coupling stent 202 is seen in greater detail in a contracted state in
Device attachment to the native valve structure is achieved using a balloon catheter to expand and deploy the stent covered by a fabric (e.g., Dacron) skirt 218. In the views of FIGS. 17F and 18-19, the fabric skirt 218 surrounds the outside of the stent 202, and is shown in phantom, but may also be provided on the inside of the stent. The main functions of this sleeve 218 are to help prevent paravalvular leaks and provide means to securely encapsulate any Calcium nodules on the aortic valve leaflets (if left in place) and/or the aortic valve annulus.
As best seen in
The stent 202 may be similar to an expandable Stainless Steel stent used in the Edwards SAPIEN Transcatheter Heart Valve. However, the material is not limited to Stainless Steel, and other materials such as Co—Cr alloys, etc. may be used.
The minimum I.D. of the upper end 245 of the covered stent 202 will always be bigger than the I.D. of the prosthetic valve 208 to which it attaches. For instance, if the upper end 245 secures to the underside of the suture-permeable ring 216, which surrounds the support structure 212 of the valve, it will by definition be larger than the I.D. of the support structure 212.
It should be noted that a plastically-expandable stent 202 desirably provides sufficient anchoring force for the heart valve 200, and also permits some expansion of the annulus itself. That said, a self-expanding material may be used, though such a stent would likely require supplemental coupling means, such as barbs, staples, etc.
The system 300 in
The present application describes an essentially rigid delivery system in that the handle 306 is preferably made of rigid polymer such as polypropylene. An alternative system contemplates a flexible delivery system that may be bent out of the way and have a length of up to 800 mm. The diameter of such a delivery system will not be as small as previous percutaneous devices, as the primary access route is through a direct access pathway and small diameters are not necessary.
The system 300 also includes a two-piece handle assembly 306 that combines the aforementioned distal section 240 mated with the proximal section 244. The handle components are further described with reference to
In use, the prosthetic heart valve 200 (or valve 30) is selected based on type and size. Typically, the heart valve 200 includes bioprosthetic leaflets, such as bovine pericardium leaflets, and remains stored in a preservative solution in a contaminant-free jar. If the holder 206 attaches to the valve with sutures, as preferred, the holder also resides in the jar during storage and shipping.
After the surgeon stops the heart and exposes and measures the annulus for size, he/she selects a valve size that is larger than the annulus. Technicians open the jar containing the selected valve and snap the distal handle section 240 into the holder hub 227 while the combination of the heart valve 200 and holder 206 is still in the jar. The resulting assembly facilitates handling of the bio-prosthesis during pre-procedure preparations (i.e. rinsing steps, etc.). The grip 312 on the distal handle section 240 facilitates these preparation steps.
The surgeon places guiding sutures 230 into the annulus at the cusp locations, and then back out and through the valve sewing ring in the corresponding locations. The surgeon slides the valve down the guiding sutures 230 using the distal end 240 of the handle assembly 306 to press the valve into position within the annulus, as seen in
In the case of the first embodiment, where the unitary heart valve 30 mounts on a balloon catheter 32, the proximal section 62 that incorporates the balloon 40 pre-assembled in its central lumen snaps onto the distal section 64 to form the hollow handle 60. As both handle pieces are snapped together, the balloon catheter with its wrapped balloon is encapsulated in the handle shaft formed by the two mating handle pieces.
The delivery system 300 provides two positions for the balloon catheter:
a) A retracted balloon position used at the pre coupling stent deployment stage of the procedure.
b) An advanced balloon position used for coupling stent deployment. The advanced position is used once the heart valve 200 has been placed in the desired aortic root position and balloon expansion is required to expand the coupling stent and secure the implant in place.
When proper placement of the valve 200 is insured, the surgeon inflates the balloon 262 using saline or similar expedient to its maximum size, or with a predetermined volume of inflation fluid. This expands the coupling stent 202 to its implant size against the annulus (or leaflets). Thereafter, the balloon 262 is deflated and removed from within the heart valve 200. Upon completing deployment, the valve holder sutures are cut with a scalpel and the delivery system 300 retracted through valve leaflets to complete the deployment procedure.
In another advantageous feature, the two-component valve system illustrated in the preceding figures provides a device and method that substantially reduces the time of the surgical procedure as compared with replacement valves that are sutured to the tissue after removing the native leaflets. For example, the coupling stent 36, 202 may be deployed quickly such that the heart valve 200, 30 may be rapidly attached to the annulus. This reduces the time required on extracorporeal circulation and thereby substantially reduces the risk to the patient.
In addition to speeding up the implant process, the present invention having the valve and its robust plastically-expandable stent, permits the annulus to be expanded to accommodate a larger valve than otherwise would be possible. In particular, clinical research has shown that the left ventricular outflow tract (LVOT) can be significantly expanded by a balloon-expandable stent and still retain normal functioning. In this context, “significantly expanding” the LVOT means expanding it by at least 5%, more preferably between about 5-30%, and typically between 10-20%. In absolute terms, the LVOT may be expanded 1.0-5 mm depending on the nominal orifice size. This expansion of the annulus creates an opportunity to increase the size of a surgically implanted prosthetic valve. The present invention employs a balloon-expandable valve stent which permits expansion of the LVOT at and just below the aortic annulus, at the inflow end of the prosthetic valve. The interference fit created between the outside of the coupling stent and the LVOT secures the valve, desirably without pledgets or sutures taking up space, thereby allowing for placement of the maximum possible valve size. A larger valve size than would otherwise be available with conventional surgery enhances volumetric blood flow and reduces the pressure gradient through the valve.
It will be appreciated by those skilled in the art that embodiments of the present invention provide important new devices and methods wherein a valve may be securely anchored to a body lumen in a quick and efficient manner. Embodiments of the present invention provide a means for implanting a prosthetic valve in a surgical procedure with as few as three sutures rather than the 12-24 sutures typically used for aortic valve replacement. Accordingly, the surgical procedure time is substantially decreased. Furthermore, in addition to providing a coupling stent for the valve, the stent may be used to maintain the native valve in a dilated condition. As a result, it is not necessary for the surgeon to remove the native leaflets, thereby further reducing the procedure time.
It will also be appreciated that the present invention provides an improved system wherein a valve member may be replaced in a more quick and efficient manner. More particularly, it is not necessary to cut any sutures in order to remove the valve. Rather, the valve member may be disconnected from the coupling stent and a new valve member may be connected in its place. This is an important advantage when using biological tissue valves or other valves having limited design lives.
The variations on quick-connect heart valves, systems and methods may change based on surgeon preferences, empirical testing, economies, etc. Several possible variations include:
a) A stent frame that provides attachment means and also prevents native, calcified leaflets to interfere with flow.
b) A secondary piece mounted on the aortic side of the suturing ring to help improve attachment.
The present application encompasses numerous ways to couple the prosthetic valve 208 to the coupling stent 202, as mentioned above. However, a preferred version includes attaching the coupling stent 202 to the inflow end of valve 208 with sutures, as will be described with reference to
Note that in this version the upper end 245 of the stent 202 follows an undulating path with peaks and troughs that generally corresponds to the undulating contour of the underside of the sewing ring 216. Therefore, the temporary sutures 350 ensure that the peaks of the upper end 245 of the stent 202 match the troughs of the sewing ring 216, which are located under the commissures 214 of the valve.
Continue the stitches at every stent hole and the between every stent hole making 36 stitches, as illustrated in
No gap is left between the stitches on the sewing ring 216 area, as seen in
While the invention has been described in its preferred embodiments, it is to be understood that the words which have been used are words of description and not of limitation. Therefore, changes may be made within the appended claims without departing from the true scope of the invention.
This application is a continuation of U.S. Pat. No. 8,348,998 issued on Jan. 8, 2013, filed Jun. 23, 2010, which claims priority to U.S. Provisional Application No. 61/220,968, filed Jun. 26, 2009, the entire disclosures of which are incorporated by reference herewith.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3143742 | Cromie | Aug 1964 | A |
| 3320972 | High et al. | May 1967 | A |
| 3371352 | Siposs et al. | Mar 1968 | A |
| 3409013 | Berry | Nov 1968 | A |
| 3546710 | Shumakov et al. | Dec 1970 | A |
| 3574865 | Hamaker | Apr 1971 | A |
| 3628535 | Ostrowsky et al. | Dec 1971 | A |
| 3657744 | Ersek | Apr 1972 | A |
| 3686740 | Shiley | Aug 1972 | A |
| 3755823 | Hancock | Sep 1973 | A |
| 3839741 | Haller | Oct 1974 | A |
| 3997923 | Possis | Dec 1976 | A |
| 4035849 | Angell et al. | Jul 1977 | A |
| 4078468 | Civitello | Mar 1978 | A |
| 4079468 | Liotta et al. | Mar 1978 | A |
| 4084268 | Ionescu et al. | Apr 1978 | A |
| 4106129 | Carpentier et al. | Aug 1978 | A |
| 4172295 | Batten | Oct 1979 | A |
| 4217665 | Bex et al. | Aug 1980 | A |
| 4218782 | Rygg | Aug 1980 | A |
| 4259753 | Liotta et al. | Apr 1981 | A |
| RE30912 | Hancock | Apr 1982 | E |
| 4343048 | Ross et al. | Aug 1982 | A |
| 4364126 | Rosen et al. | Dec 1982 | A |
| 4388735 | Ionescu et al. | Jun 1983 | A |
| 4441216 | Ionescu et al. | Apr 1984 | A |
| 4451936 | Carpentier et al. | Jun 1984 | A |
| 4470157 | Love | Sep 1984 | A |
| 4501030 | Lane | Feb 1985 | A |
| 4506394 | Bedard | Mar 1985 | A |
| 4535483 | Klawitter et al. | Aug 1985 | A |
| 4605407 | Black et al. | Aug 1986 | A |
| 4626255 | Reichart et al. | Dec 1986 | A |
| 4629459 | Ionescu et al. | Dec 1986 | A |
| 4680031 | Alonso | Jul 1987 | A |
| 4702250 | Ovil et al. | Oct 1987 | A |
| 4705516 | Barone et al. | Nov 1987 | A |
| 4725274 | Lane et al. | Feb 1988 | A |
| 4731074 | Rousseau et al. | Mar 1988 | A |
| 4778461 | Pietsch et al. | Oct 1988 | A |
| 4790843 | Carpentier et al. | Dec 1988 | A |
| 4851000 | Gupta | Jul 1989 | A |
| 4865600 | Carpentier et al. | Sep 1989 | A |
| 4888009 | Lederman et al. | Dec 1989 | A |
| 4914097 | Oda et al. | Apr 1990 | A |
| 4960424 | Grooters | Oct 1990 | A |
| 4993428 | Arms | Feb 1991 | A |
| 5010892 | Colvin et al. | Apr 1991 | A |
| 5032128 | Alonso | Jul 1991 | A |
| 5037434 | Lane | Aug 1991 | A |
| 5147391 | Lane | Sep 1992 | A |
| 5163955 | Love et al. | Nov 1992 | A |
| 5258023 | Reger | Nov 1993 | A |
| 5316016 | Adams et al. | May 1994 | A |
| 5326370 | Love et al. | Jul 1994 | A |
| 5326371 | Love et al. | Jul 1994 | A |
| 5332402 | Teitelbaum | Jul 1994 | A |
| 5370685 | Stevens | Dec 1994 | A |
| 5376112 | Duran | Dec 1994 | A |
| 5396887 | Imran | Mar 1995 | A |
| 5397351 | Pavcnik et al. | Mar 1995 | A |
| 5411522 | Trott | May 1995 | A |
| 5423887 | Love et al. | Jun 1995 | A |
| 5425741 | Lemp et al. | Jun 1995 | A |
| 5431676 | Dubrul et al. | Jul 1995 | A |
| 5449384 | Johnson | Sep 1995 | A |
| 5449385 | Religa et al. | Sep 1995 | A |
| 5469868 | Reger | Nov 1995 | A |
| 5476510 | Eberhardt et al. | Dec 1995 | A |
| 5488789 | Religa et al. | Feb 1996 | A |
| 5489297 | Duran | Feb 1996 | A |
| 5489298 | Love et al. | Feb 1996 | A |
| 5500016 | Fisher | Mar 1996 | A |
| 5533515 | Coller et al. | Jul 1996 | A |
| 5549665 | Vesely et al. | Aug 1996 | A |
| 5562729 | Purdy et al. | Oct 1996 | A |
| 5571215 | Sterman et al. | Nov 1996 | A |
| 5573007 | Bobo, Sr. | Nov 1996 | A |
| 5578076 | Krueger et al. | Nov 1996 | A |
| 5584803 | Stevens et al. | Dec 1996 | A |
| 5618307 | Donlon et al. | Apr 1997 | A |
| 5626607 | Malecki et al. | May 1997 | A |
| 5628789 | Vanney et al. | May 1997 | A |
| 5693090 | Unsworth et al. | Dec 1997 | A |
| 5695503 | Krueger et al. | Dec 1997 | A |
| 5713952 | Vanney et al. | Feb 1998 | A |
| 5716370 | Williamson, IV et al. | Feb 1998 | A |
| 5728064 | Burns et al. | Mar 1998 | A |
| 5728151 | Garrison et al. | Mar 1998 | A |
| 5735894 | Krueger et al. | Apr 1998 | A |
| 5752522 | Murphy | May 1998 | A |
| 5755782 | Love et al. | May 1998 | A |
| 5766240 | Johnson | Jun 1998 | A |
| 5776187 | Krueger et al. | Jul 1998 | A |
| 5776188 | Shepherd et al. | Jul 1998 | A |
| 5800527 | Jansen et al. | Sep 1998 | A |
| 5814097 | Sterman et al. | Sep 1998 | A |
| 5814098 | Hinnenkamp et al. | Sep 1998 | A |
| 5824064 | Taheri | Oct 1998 | A |
| 5840081 | Andersen et al. | Nov 1998 | A |
| 5848969 | Panescu et al. | Dec 1998 | A |
| 5855563 | Kaplan et al. | Jan 1999 | A |
| 5855601 | Bessler et al. | Jan 1999 | A |
| 5865801 | Houser | Feb 1999 | A |
| 5891160 | Williamson, IV et al. | Apr 1999 | A |
| 5895420 | Mirsch, II et al. | Apr 1999 | A |
| 5902308 | Murphy | May 1999 | A |
| 5908450 | Gross et al. | Jun 1999 | A |
| 5919147 | Jain | Jul 1999 | A |
| 5921934 | Teo | Jul 1999 | A |
| 5921935 | Hickey | Jul 1999 | A |
| 5924984 | Rao | Jul 1999 | A |
| 5957949 | Leonhardt et al. | Sep 1999 | A |
| 5972004 | Williamson, IV et al. | Oct 1999 | A |
| 5984959 | Robertson et al. | Nov 1999 | A |
| 5984973 | Girard et al. | Nov 1999 | A |
| 6010531 | Donlon et al. | Jan 2000 | A |
| 6042607 | Williamson, IV et al. | Mar 2000 | A |
| 6059827 | Fenton, Jr. | May 2000 | A |
| 6066160 | Colvin et al. | May 2000 | A |
| 6074418 | Buchanan et al. | Jun 2000 | A |
| 6081737 | Shah | Jun 2000 | A |
| 6083179 | Oredsson | Jul 2000 | A |
| 6099475 | Seward et al. | Aug 2000 | A |
| 6106550 | Magovern et al. | Aug 2000 | A |
| 6110200 | Hinnenkamp | Aug 2000 | A |
| 6117091 | Young et al. | Sep 2000 | A |
| 6162233 | Williamson, IV et al. | Dec 2000 | A |
| 6168614 | Andersen et al. | Jan 2001 | B1 |
| 6176877 | Buchanan et al. | Jan 2001 | B1 |
| 6197054 | Hamblin, Jr. et al. | Mar 2001 | B1 |
| 6217611 | Klostermeyer | Apr 2001 | B1 |
| 6231561 | Frazier et al. | May 2001 | B1 |
| 6241765 | Griffin et al. | Jun 2001 | B1 |
| 6245102 | Jayaraman | Jun 2001 | B1 |
| 6283127 | Sterman et al. | Sep 2001 | B1 |
| 6287339 | Vazquez et al. | Sep 2001 | B1 |
| 6290674 | Roue et al. | Sep 2001 | B1 |
| 6312447 | Grimes | Nov 2001 | B1 |
| 6312465 | Griffin et al. | Nov 2001 | B1 |
| 6328727 | Frazier et al. | Dec 2001 | B1 |
| 6371983 | Lane | Apr 2002 | B1 |
| 6402780 | Williamson, IV et al. | Jun 2002 | B2 |
| 6425916 | Garrison et al. | Jul 2002 | B1 |
| 6440164 | DiMatteo et al. | Aug 2002 | B1 |
| 6454799 | Schreck | Sep 2002 | B1 |
| 6458153 | Bailey et al. | Oct 2002 | B1 |
| 6468305 | Otte | Oct 2002 | B1 |
| 6530952 | Vesely | Mar 2003 | B2 |
| 6558429 | Taylor | May 2003 | B2 |
| 6569196 | Vesely | May 2003 | B1 |
| 6582462 | Andersen et al. | Jun 2003 | B1 |
| 6585766 | Huynh et al. | Jul 2003 | B1 |
| 6652578 | Bailey et al. | Nov 2003 | B2 |
| 6682559 | Myers et al. | Jan 2004 | B2 |
| 6685739 | DiMatteo et al. | Feb 2004 | B2 |
| 6719789 | Cox | Apr 2004 | B2 |
| 6730118 | Spenser et al. | May 2004 | B2 |
| 6733525 | Yang et al. | May 2004 | B2 |
| 6764508 | Roehe et al. | Jul 2004 | B1 |
| 6767362 | Schreck | Jul 2004 | B2 |
| 6786925 | Schoon et al. | Sep 2004 | B1 |
| 6790229 | Berreklouw | Sep 2004 | B1 |
| 6790230 | Beyersdorf et al. | Sep 2004 | B2 |
| 6805711 | Quijano et al. | Oct 2004 | B2 |
| 6846325 | Liddicoat | Jan 2005 | B2 |
| 6893459 | Macoviak | May 2005 | B1 |
| 6893460 | Spenser et al. | May 2005 | B2 |
| 6908481 | Cribier | Jun 2005 | B2 |
| 6936067 | Buchanan | Aug 2005 | B2 |
| 6939365 | Fogarty et al. | Sep 2005 | B1 |
| 6964682 | Nguyen-Thien-Nhon et al. | Nov 2005 | B2 |
| 6974476 | McGuckin, Jr. et al. | Dec 2005 | B2 |
| 6978176 | Lattouf | Dec 2005 | B2 |
| 7011681 | Vesely | Mar 2006 | B2 |
| 7018406 | Seguin et al. | Mar 2006 | B2 |
| 7025780 | Gabbay | Apr 2006 | B2 |
| 7070616 | Majercak et al. | Jul 2006 | B2 |
| 7081131 | Thornton | Jul 2006 | B2 |
| 7097659 | Woolfson et al. | Aug 2006 | B2 |
| 7101396 | Artof et al. | Sep 2006 | B2 |
| 7147663 | Berg et al. | Dec 2006 | B1 |
| 7153324 | Case et al. | Dec 2006 | B2 |
| 7160320 | Duran | Jan 2007 | B2 |
| 7172625 | Shu et al. | Feb 2007 | B2 |
| 7195641 | Palmaz et al. | Mar 2007 | B2 |
| 7201771 | Lane | Apr 2007 | B2 |
| 7201772 | Schwammenthal et al. | Apr 2007 | B2 |
| 7238200 | Lee et al. | Jul 2007 | B2 |
| 7252682 | Seguin | Aug 2007 | B2 |
| 7261732 | Justino | Aug 2007 | B2 |
| 7311730 | Gabbay | Dec 2007 | B2 |
| RE40377 | Williamson, IV et al. | Jun 2008 | E |
| 7422603 | Lane | Sep 2008 | B2 |
| 7429269 | Schwammenthal et al. | Sep 2008 | B2 |
| 7442204 | Schwammenthal et al. | Oct 2008 | B2 |
| 7445630 | Lashinski et al. | Nov 2008 | B2 |
| 7468073 | Johnson et al. | Dec 2008 | B2 |
| 7470285 | Nugent et al. | Dec 2008 | B2 |
| 7510575 | Spenser et al. | Mar 2009 | B2 |
| 7513909 | Lane et al. | Apr 2009 | B2 |
| 7534261 | Friedman | May 2009 | B2 |
| 7556647 | Drews et al. | Jul 2009 | B2 |
| 7569072 | Berg et al. | Aug 2009 | B2 |
| 7578843 | Shu | Aug 2009 | B2 |
| 7585321 | Cribier | Sep 2009 | B2 |
| 7597711 | Drews et al. | Oct 2009 | B2 |
| 7611535 | Woolfson et al. | Nov 2009 | B2 |
| 7658763 | Stobie | Feb 2010 | B2 |
| 7682390 | Seguin | Mar 2010 | B2 |
| 7708775 | Rowe et al. | May 2010 | B2 |
| 8167932 | Bourang et al. | May 2012 | B2 |
| 8348998 | Pintor et al. | Jan 2013 | B2 |
| 8696742 | Pintor et al. | Apr 2014 | B2 |
| 20010021872 | Bailey et al. | Sep 2001 | A1 |
| 20010039435 | Roue et al. | Nov 2001 | A1 |
| 20010039436 | Frazier et al. | Nov 2001 | A1 |
| 20010041914 | Frazier et al. | Nov 2001 | A1 |
| 20010041915 | Roue et al. | Nov 2001 | A1 |
| 20010049492 | Frazier et al. | Dec 2001 | A1 |
| 20020026238 | Lane et al. | Feb 2002 | A1 |
| 20020032481 | Gabbay | Mar 2002 | A1 |
| 20020058995 | Stevens | May 2002 | A1 |
| 20020123802 | Snyders | Sep 2002 | A1 |
| 20020138138 | Yang | Sep 2002 | A1 |
| 20020151970 | Garrison et al. | Oct 2002 | A1 |
| 20020188348 | DiMatteo et al. | Dec 2002 | A1 |
| 20020198594 | Schreck | Dec 2002 | A1 |
| 20030014104 | Cribier | Jan 2003 | A1 |
| 20030023300 | Bailey et al. | Jan 2003 | A1 |
| 20030023303 | Palmaz et al. | Jan 2003 | A1 |
| 20030036795 | Andersen et al. | Feb 2003 | A1 |
| 20030040792 | Gabbay | Feb 2003 | A1 |
| 20030055495 | Pease et al. | Mar 2003 | A1 |
| 20030109924 | Cribier | Jun 2003 | A1 |
| 20030114913 | Spenser et al. | Jun 2003 | A1 |
| 20030130729 | Paniagua et al. | Jul 2003 | A1 |
| 20030149478 | Figulla et al. | Aug 2003 | A1 |
| 20030167089 | Lane | Sep 2003 | A1 |
| 20030236568 | Hojeibane et al. | Dec 2003 | A1 |
| 20040019374 | Hojeibane et al. | Jan 2004 | A1 |
| 20040034411 | Quijano et al. | Feb 2004 | A1 |
| 20040044406 | Woolfson et al. | Mar 2004 | A1 |
| 20040106976 | Bailey et al. | Jun 2004 | A1 |
| 20040122514 | Fogarty et al. | Jun 2004 | A1 |
| 20040122516 | Fogarty et al. | Jun 2004 | A1 |
| 20040167573 | Williamson et al. | Aug 2004 | A1 |
| 20040186563 | Lobbi | Sep 2004 | A1 |
| 20040186565 | Schreck | Sep 2004 | A1 |
| 20040193261 | Berreklouw | Sep 2004 | A1 |
| 20040206363 | McCarthy et al. | Oct 2004 | A1 |
| 20040210304 | Seguin et al. | Oct 2004 | A1 |
| 20040210307 | Khairkhahan | Oct 2004 | A1 |
| 20040225355 | Stevens | Nov 2004 | A1 |
| 20040236411 | Sarac et al. | Nov 2004 | A1 |
| 20040260389 | Case et al. | Dec 2004 | A1 |
| 20040260390 | Sarac et al. | Dec 2004 | A1 |
| 20050010285 | Lambrecht et al. | Jan 2005 | A1 |
| 20050027348 | Case et al. | Feb 2005 | A1 |
| 20050033398 | Seguin | Feb 2005 | A1 |
| 20050043760 | Fogarty et al. | Feb 2005 | A1 |
| 20050043790 | Seguin | Feb 2005 | A1 |
| 20050060029 | Le et al. | Mar 2005 | A1 |
| 20050065594 | DiMatteo et al. | Mar 2005 | A1 |
| 20050065614 | Stinson | Mar 2005 | A1 |
| 20050075584 | Cali | Apr 2005 | A1 |
| 20050075713 | Biancucci et al. | Apr 2005 | A1 |
| 20050075717 | Nguyen et al. | Apr 2005 | A1 |
| 20050075718 | Nguyen et al. | Apr 2005 | A1 |
| 20050075719 | Bergheim | Apr 2005 | A1 |
| 20050075720 | Nguyen et al. | Apr 2005 | A1 |
| 20050075724 | Svanidze et al. | Apr 2005 | A1 |
| 20050080454 | Drews et al. | Apr 2005 | A1 |
| 20050096738 | Cali et al. | May 2005 | A1 |
| 20050137682 | Justino | Jun 2005 | A1 |
| 20050137686 | Salahieh et al. | Jun 2005 | A1 |
| 20050137687 | Salahieh et al. | Jun 2005 | A1 |
| 20050137688 | Salahieh et al. | Jun 2005 | A1 |
| 20050137689 | Salahieh et al. | Jun 2005 | A1 |
| 20050137690 | Salahieh et al. | Jun 2005 | A1 |
| 20050137691 | Salahieh et al. | Jun 2005 | A1 |
| 20050137692 | Haug et al. | Jun 2005 | A1 |
| 20050137694 | Haug et al. | Jun 2005 | A1 |
| 20050137695 | Salahieh et al. | Jun 2005 | A1 |
| 20050137702 | Haug et al. | Jun 2005 | A1 |
| 20050159811 | Lane | Jul 2005 | A1 |
| 20050165477 | Anduiza et al. | Jul 2005 | A1 |
| 20050165479 | Drews et al. | Jul 2005 | A1 |
| 20050182483 | Osborne et al. | Aug 2005 | A1 |
| 20050182486 | Gabbay | Aug 2005 | A1 |
| 20050192665 | Spenser et al. | Sep 2005 | A1 |
| 20050203616 | Cribier | Sep 2005 | A1 |
| 20050203617 | Forster et al. | Sep 2005 | A1 |
| 20050203618 | Sharkawy et al. | Sep 2005 | A1 |
| 20050216079 | MaCoviak | Sep 2005 | A1 |
| 20050222674 | Paine | Oct 2005 | A1 |
| 20050234546 | Nugent et al. | Oct 2005 | A1 |
| 20050240259 | Sisken et al. | Oct 2005 | A1 |
| 20050251252 | Stobie | Nov 2005 | A1 |
| 20050261765 | Liddicoat | Nov 2005 | A1 |
| 20050283231 | Haug et al. | Dec 2005 | A1 |
| 20060025857 | Bergheim et al. | Feb 2006 | A1 |
| 20060052867 | Revuelta et al. | Mar 2006 | A1 |
| 20060058871 | Zakay et al. | Mar 2006 | A1 |
| 20060058872 | Salahieh et al. | Mar 2006 | A1 |
| 20060074484 | Huber | Apr 2006 | A1 |
| 20060085060 | Campbell | Apr 2006 | A1 |
| 20060095125 | Chinn et al. | May 2006 | A1 |
| 20060122634 | Ino et al. | Jun 2006 | A1 |
| 20060122692 | Gilad et al. | Jun 2006 | A1 |
| 20060127756 | Seo | Jun 2006 | A1 |
| 20060136054 | Berg et al. | Jun 2006 | A1 |
| 20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
| 20060154230 | Cunanan et al. | Jul 2006 | A1 |
| 20060161249 | Realyvasquez et al. | Jul 2006 | A1 |
| 20060167543 | Bailey et al. | Jul 2006 | A1 |
| 20060173537 | Yang et al. | Aug 2006 | A1 |
| 20060195183 | Navia et al. | Aug 2006 | A1 |
| 20060195184 | Lane et al. | Aug 2006 | A1 |
| 20060195185 | Lane et al. | Aug 2006 | A1 |
| 20060195186 | Drews et al. | Aug 2006 | A1 |
| 20060207031 | Cunanan et al. | Sep 2006 | A1 |
| 20060229708 | Powell et al. | Oct 2006 | A1 |
| 20060235508 | Lane et al. | Oct 2006 | A1 |
| 20060241745 | Solem | Oct 2006 | A1 |
| 20060246888 | Bender et al. | Nov 2006 | A1 |
| 20060253191 | Salahieh et al. | Nov 2006 | A1 |
| 20060259134 | Schwammenthal et al. | Nov 2006 | A1 |
| 20060259135 | Navia et al. | Nov 2006 | A1 |
| 20060259136 | Nguyen et al. | Nov 2006 | A1 |
| 20060265056 | Nguyen et al. | Nov 2006 | A1 |
| 20060271172 | Tehrani | Nov 2006 | A1 |
| 20060271175 | Woolfson et al. | Nov 2006 | A1 |
| 20060287717 | Rowe et al. | Dec 2006 | A1 |
| 20060287719 | Rowe et al. | Dec 2006 | A1 |
| 20070005129 | Damm et al. | Jan 2007 | A1 |
| 20070010876 | Salahieh et al. | Jan 2007 | A1 |
| 20070010877 | Salahieh et al. | Jan 2007 | A1 |
| 20070016285 | Lane et al. | Jan 2007 | A1 |
| 20070016286 | Herrmann et al. | Jan 2007 | A1 |
| 20070016288 | Gurskis et al. | Jan 2007 | A1 |
| 20070043435 | Seguin et al. | Feb 2007 | A1 |
| 20070078509 | Lotfy | Apr 2007 | A1 |
| 20070078510 | Ryan | Apr 2007 | A1 |
| 20070100440 | Figulla et al. | May 2007 | A1 |
| 20070129794 | Realyvasquez | Jun 2007 | A1 |
| 20070142906 | Figulla et al. | Jun 2007 | A1 |
| 20070142907 | Moaddeb et al. | Jun 2007 | A1 |
| 20070150053 | Gurskis et al. | Jun 2007 | A1 |
| 20070156233 | Kapadia et al. | Jul 2007 | A1 |
| 20070162103 | Case et al. | Jul 2007 | A1 |
| 20070162107 | Haug et al. | Jul 2007 | A1 |
| 20070162111 | Fukamachi et al. | Jul 2007 | A1 |
| 20070179604 | Lane | Aug 2007 | A1 |
| 20070185565 | Schwammenthal et al. | Aug 2007 | A1 |
| 20070198097 | Zegdi | Aug 2007 | A1 |
| 20070203575 | Forster et al. | Aug 2007 | A1 |
| 20070203576 | Lee et al. | Aug 2007 | A1 |
| 20070213813 | Von Segesser et al. | Sep 2007 | A1 |
| 20070225801 | Drews et al. | Sep 2007 | A1 |
| 20070233237 | Krivoruchko | Oct 2007 | A1 |
| 20070239266 | Birdsall | Oct 2007 | A1 |
| 20070239269 | Dolan et al. | Oct 2007 | A1 |
| 20070239273 | Allen | Oct 2007 | A1 |
| 20070244558 | Machiraju | Oct 2007 | A1 |
| 20070255398 | Yang et al. | Nov 2007 | A1 |
| 20070260305 | Drews et al. | Nov 2007 | A1 |
| 20070265701 | Gurskis et al. | Nov 2007 | A1 |
| 20070270944 | Bergheim et al. | Nov 2007 | A1 |
| 20070282436 | Pinchuk | Dec 2007 | A1 |
| 20070288089 | Gurskis et al. | Dec 2007 | A1 |
| 20080021546 | Patz et al. | Jan 2008 | A1 |
| 20080033543 | Gurskis et al. | Feb 2008 | A1 |
| 20080065198 | Quintessenza | Mar 2008 | A1 |
| 20080119875 | Ino et al. | May 2008 | A1 |
| 20080281411 | Berreklouw | Nov 2008 | A1 |
| 20080319543 | Lane | Dec 2008 | A1 |
| 20090036903 | Ino et al. | Feb 2009 | A1 |
| 20090192599 | Lane et al. | Jul 2009 | A1 |
| 20090192602 | Kuehn | Jul 2009 | A1 |
| 20090192603 | Ryan | Jul 2009 | A1 |
| 20090192604 | Gloss | Jul 2009 | A1 |
| 20090192605 | Gloss et al. | Jul 2009 | A1 |
| 20090192606 | Gloss et al. | Jul 2009 | A1 |
| 20100161036 | Pintor et al. | Jun 2010 | A1 |
| 20100249894 | Oba et al. | Sep 2010 | A1 |
| 20100249908 | Chau et al. | Sep 2010 | A1 |
| 20110147251 | Hodshon et al. | Jun 2011 | A1 |
| 20120065729 | Pintor et al. | Mar 2012 | A1 |
| 20120150288 | Hodshon et al. | Jun 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 0084395 | Jul 1983 | EP |
| 0096721 | Dec 1983 | EP |
| 0125393 | Nov 1984 | EP |
| 0143246 | Jun 1985 | EP |
| 0179562 | Apr 1986 | EP |
| 1171059 | Jan 2002 | EP |
| 2056023 | Mar 1981 | GB |
| 2069843 | Sep 1981 | GB |
| 2254254 | Oct 1992 | GB |
| 2279134 | Dec 1994 | GB |
| 1116573 | Jul 1985 | SU |
| 1697790 | Dec 1991 | SU |
| 8900840 | Feb 1989 | WO |
| 9115167 | Oct 1991 | WO |
| 9212690 | Aug 1992 | WO |
| 9213502 | Aug 1992 | WO |
| 9219184 | Nov 1992 | WO |
| 9219185 | Nov 1992 | WO |
| 9517139 | Jun 1995 | WO |
| 9528899 | Nov 1995 | WO |
| 9640006 | Dec 1996 | WO |
| 9709933 | Mar 1997 | WO |
| 9709944 | Mar 1997 | WO |
| 9727799 | Aug 1997 | WO |
| 9741801 | Nov 1997 | WO |
| 9742871 | Nov 1997 | WO |
| 9806329 | Feb 1998 | WO |
| 9911201 | Mar 1999 | WO |
| 9915112 | Apr 1999 | WO |
| 9951169 | Oct 1999 | WO |
| 0032105 | Jun 2000 | WO |
| 0040176 | Jul 2000 | WO |
| 0060995 | Oct 2000 | WO |
| 0154624 | Aug 2001 | WO |
| 0154625 | Aug 2001 | WO |
| 02076347 | Oct 2002 | WO |
| 2006086135 | Aug 2006 | WO |
| Entry |
|---|
| Krakow, “3F Therapeutics, Inc. Announces the First Clinical Implantation of the 3F Enable Aortic Heart Valve. TM., a Patented, Sutureless Implantation, Replacement Heart Valve Intended to Save Valuable Surgery Time and Reduce Time RelatedComplications . . . ” Healthcare Sales & Marketing Network News Feed, Jan. 18, 2005, pp. 1-2. |
| Sadowski, Jerzy; Kapelak, Boguslaw; Bartus, Krzysztof, “Sutureless Heart Valve Implantation—A Case Study,” Touch Briefings, 2005, pp. 48-50. |
| Number | Date | Country | |
|---|---|---|---|
| 20130116777 A1 | May 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61220968 | Jun 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12821628 | Jun 2010 | US |
| Child | 13723799 | US |
